causal

PBMs block cheaper biosimilars to protect rebate revenue

PBMs keep high-cost drugs on formulary and exclude cheaper biosimilars because they earn rebates on the expensive drug but not the cheaper alternative — for example Humira at $8,000/month pre-rebate (3-6k after rebate) versus the biosimilar Yusimry at $594, which the big three PBMs won't allow because there's no rebate, so they make more money keeping patients on the costly drug.

causalpending

Speaker

Mark Cuban

Evidence Quote

“Humira, the pre-rebate price is about $8,000 per month. After rebates... it'll be anywhere from three to $6,000 a month. You can go to get your doctor to prescribe that biosimilar Yusimry and you pay $594.”

Source

Mark Cuban— Lex Fridman Podcast
Created: 6/13/2026, 3:37:54 AM

Your notes

Loading notes...